Physician profile
Janaki Kanumilli
NPI 1912956889
$9,059.15
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $743 · 2021: $3,012 · 2022: $1,686 · 2023: $1,662 · 2024: $97.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,330.73 | 2021 | |
| Abbvie INC. | $1,262.80 | 2021-2024 | |
| Lilly USA, LLC | $847.56 | 2019-2023 | Mounjaro |
| Neurocrine Biosciences, INC. | $511.21 | 2019-2023 | Ongentys |
| Novo Nordisk INC | $501.28 | 2020-2023 | Rybelsus, Ozempic |
| Eisai INC. | $485.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $418.19 | 2019-2023 | Breztri |
| Allergan, INC. | $418.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.29 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.81 | 2022-2023 | |
| Glaxosmithkline, LLC. | $261.48 | 2023 | Trelegy Ellipta |
| Sk Life Science, INC. | $257.71 | 2021-2022 | |
| Intuity Medical INC | $233.15 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Novartis Pharmaceuticals Corporation | $189.35 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $149.01 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $142.00 | 2023 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $132.30 | 2022 | |
| Aurinia Pharma U.S., INC. | $125.00 | 2022 | |
| Abbott Laboratories | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $124.70 | 2023 | Tepezza |
| Teva Pharmaceuticals USA, INC. | $115.54 | 2019-2023 | Austedo |
| Merck Sharp & Dohme LLC | $111.36 | 2019-2021 | |
| Acorda Therapeutics, INC | $105.75 | 2019-2023 | Inbrija |
| Neurelis, INC. | $96.50 | 2021-2024 | Valtoco |
| Amgen INC. | $75.20 | 2019-2022 | |
| Mdd US Operations, LLC | $75.13 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $63.77 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $52.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $44.30 | 2020 | |
| Lundbeck LLC | $41.06 | 2020-2022 | |
| Ge Healthcare | $31.07 | 2019 | |
| Ucb, INC. | $30.67 | 2020 | |
| Genzyme Corporation | $22.30 | 2021 | |
| Biogen, INC. | $18.13 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.95 | 2020 | |
| Grifols USA, LLC | $16.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.56 | 2020 | |
| Pfizer INC. | $14.63 | 2023 | |
| Boston Scientific Corporation | $14.45 | 2019 | |
| Medtronic USA, INC. | $14.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janaki Kanumilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.